Zolbetuximab with nab-paclitaxel and gemcitabine for previously untreated metastatic CLDN18.2-positive pancreatic adenocarcinoma

Zolbetuximab in combination with nab-paclitaxel and gemcitabine is in clinical development for the treatment of Claudin (CLDN) 18.2 positive metastatic pancreatic adenocarcinoma. Pancreatic cancer is caused by the abnormal and uncontrolled growth of cells in the pancreas, a large gland that is part of the digestive system. Metastatic cancer refers to a cancer where the disease has spread from where it first started to another area of the body. Metastatic pancreatic adenocarcinoma develops from cells lining small tubes in the pancreas called ducts. These carry the digestive juices into the main pancreatic duct and then on into the first part of the small intestine. CLDN18.2 a protein that is not expressed in healthy pancreatic tissue but is expressed in 60-90% of pancreatic ductal adenocarcinomas. CLDN18.2 represents a potential target for the treatment of pancreatic adenocarcinomas.